The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by Vertex Pharmaceuticals,

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. “I think it could be a potentially groundbreaking medication,